Vedanta Biosciences is a biotechnology company that develops medicines based on live bacterial consortia that can colonize the human intestine that is headquartered in Cambridge, Massachusetts. Vedanta Biosciences was launched by PureTech Health and was founded by Ruslan Medzhitov, Alexander Rudensky, Dan Littman, Kenya Honda, and Brett Finlay.
On December 24, 2018 Vedanta Biosciences completed their series C funding round with $27 million in funding from Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health. The company plans on using the funding to develop its product candidates derived from the microbiome.
On May 13, 2019 Vedanta Biosciences completed their series C-2 funding round raising $45.5 million in funding from JSR Corporation, Shumway Capital, SymBiosis LLC, and Partners Investment Co., Ltd.. The CEO and co-founder of Vedanta Biosciences, Bernat Olle, made the following statement regarding how the company plans on using the funding:
This financing will enable us to continue to advance defined bacterial consortia as a new modality, including generating clinical readouts in multiple therapeutic areas, and we are grateful to our new and existing investors for their support.
On September 23, 2019 Vedanta Biosciences announced expanding their series C-2 funding round with $16.6 million in funding from QUAD Investment Management, SV Investment Corp., Shinhan Investment-Private Equity, Shinhan Capital-Yeollim Partners, Partners Investment Co., Ltd, FC Capital, and SymBiosis LLC. The company plans on using their additional funding to accelerate the development of its product pipeline.